Zhu, Y., Hu, H., Ding, D., Li, S., Liao, M., Shi, Y., & Huang, J. (2021). First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: A United States-based cost-effectiveness analysis. BMC.
Style de citation Chicago (17e éd.)Zhu, Youwen, Huabin Hu, Dong Ding, Shuosha Li, Mengting Liao, Yin Shi, et Jin Huang. First-line Pembrolizumab Plus Chemotherapy for Extensive-stage Small-cell Lung Cancer: A United States-based Cost-effectiveness Analysis. BMC, 2021.
Style de citation MLA (8e éd.)Zhu, Youwen, et al. First-line Pembrolizumab Plus Chemotherapy for Extensive-stage Small-cell Lung Cancer: A United States-based Cost-effectiveness Analysis. BMC, 2021.
Attention : ces citations peuvent ne pas être correctes à 100%.